BSEInsider Trading / SAST1d ago · 29 Aug 2026, 05:04 pm
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Swapan Khandelwal
Goldline Pharmaceutical Ltd · 544759
✦ AI SummaryRelated Party
Goldline Pharmaceutical Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Swapan Khandelwal.
Analysis Scores
Earnings Impact2/10
Growth Catalyst2/10
Governance Concern3/10
Regulatory Risk2/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Goldline Pharmaceutical Ltd - 544759 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011